Skip to content
RNAWiki
Checking…
All public datasets

Public dataset

Recorded source agreement and disagreement

Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.

What this does not mean: agree can mean only that sources print the same normalized reading; it is not clinical-context equivalence, independent replication, or proof. differ requires matching structured context and disjoint comparable values. not_comparable and insufficient_context are not disagreement.
Public rows
1,681
Generated
Schema version
source-consensus/2

Coverage

What this run contains

Compared medicine fields
1,681
Agree
1,282
Differ
0
Not comparable
12
Insufficient context
387
Fields represented
5
bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution

Method

How the rows were made

  1. Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
  2. One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
  3. Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
  4. not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
  5. The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
  6. Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
  7. documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.

Limits

Read these before using a row

  • Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
  • The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
  • Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
  • Only the recorded fields and source documents in this snapshot are compared.
  • A source count is the number of retained source records in the row, not a count of independent experiments.

Provenance

Source examples

abacavir · bioavailability · agree

15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
The geometric mean absolute bioavailability of the tablet was 83%.

alemtuzumab · volumeOfDistribution · not_comparable

2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)
Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).

abiraterone · halfLife · insufficient_context

31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)
Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.

Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.

Schema

Fields in the public projection

FieldTypeMeaning
medicineSlugstringStable RNAWiki medicine route key.
fieldstringRecorded pharmacokinetic field being compared.
comparisonStatestringagree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero.
comparisonReasonsstring[]Deterministic codes explaining the state.
documentsExaminednumberRecorded source documents considered for the field.
sourceCountnumberRecorded source readings represented.
agreementRatenumberShare represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability.
readingsconsensus-reading[]Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt.

Reader

Search and filter the rows

Case-insensitive text search over the public fields named for this dataset.

Exact comparability state.

Exact recorded field key.

Clear

Showing 1,041–1,050 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.

  1. Projected row 1041

    Medicine slug
    motixafortide
    Compared field
    halfLife
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    2
    Source count
    2
    Agreement rate
    1
    Recorded readings

    1. 2 hours

      Numeric value
      2
      Unit
      hours
      Source records
      2

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 2 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e704b2db-f119-40ba-9346-9229e3281c9e (opens source in a new tab)

        Motixafortide label

        Version not recorded · Effective date not recorded

        Elimination Motixafortide has an effective half-life in human plasma of approximately 2 hours.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f7cdc584-ebf0-a68e-e053-6294a90a9ea9 (opens source in a new tab)

        Motixafortide label

        Version not recorded · Effective date not recorded

        Elimination Motixafortide has an effective half-life in human plasma of approximately 2 hours.

  2. Projected row 1042

    Medicine slug
    motixafortide
    Compared field
    proteinBinding
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    2
    Source count
    2
    Agreement rate
    1
    Recorded readings

    1. 99%

      Numeric value
      99
      Unit
      %
      Source records
      2

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 2 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e704b2db-f119-40ba-9346-9229e3281c9e (opens source in a new tab)

        Motixafortide label

        Version not recorded · Effective date not recorded

        Distribution Motixafortide is highly bound to human plasma proteins (>99%).
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f7cdc584-ebf0-a68e-e053-6294a90a9ea9 (opens source in a new tab)

        Motixafortide label

        Version not recorded · Effective date not recorded

        Distribution Motixafortide is highly bound to human plasma proteins (>99%).

  3. Projected row 1043

    Medicine slug
    motixafortide
    Compared field
    volumeOfDistribution
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    2
    Source count
    2
    Agreement rate
    1
    Recorded readings

    1. 27 L

      Numeric value
      27
      Unit
      L
      Source records
      2

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 2 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e704b2db-f119-40ba-9346-9229e3281c9e (opens source in a new tab)

        Motixafortide label

        Version not recorded · Effective date not recorded

        The estimated volume of distribution of the central compartment in a typical subject is 27 L.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f7cdc584-ebf0-a68e-e053-6294a90a9ea9 (opens source in a new tab)

        Motixafortide label

        Version not recorded · Effective date not recorded

        The estimated volume of distribution of the central compartment in a typical subject is 27 L.

  4. Projected row 1044

    Medicine slug
    moxifloxacin
    Compared field
    halfLife
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    48
    Source count
    46
    Agreement rate
    0.543478
    Recorded readings

    1. 12 ± 1.3 hours

      Numeric value
      12
      Unit
      hours
      Source records
      25

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 25 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1a98b20d-c4a1-4184-8387-a4866d1d62bf (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The mean (± SD) elimination half-life from plasma is 12 ± 1.3 hours; steady-state is achieved after at least three days with a 400 mg once daily regimen.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:54377276-96bf-4140-9e90-55623ab6b013 (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The mean (± SD) elimination half-life from plasma is 12 ± 1.3 hours; steady-state is achieved after at least three days with a 400 mg once daily regimen.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ac8a81b9-2fed-412a-8c83-db8dee1061f6 (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The mean (± SD) elimination half-life from plasma is 12 ± 1.3 hours; steady-state is achieved after at least three days with a 400 mg once daily regimen.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:45ce14e5-98b8-296b-e063-6294a90a769b (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The mean (± SD) elimination half-life from plasma is 12 ± 1.3 hours; steady-state is achieved after at least three days with a 400 mg once daily regimen.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c6fa4129-2f92-4179-ac5d-bb7b4a538789 (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The mean (± SD) elimination half-life from plasma is 12 ± 1.3 hours; steady-state is achieved after at least three days with a 400 mg once daily regimen.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:656f582c-ecba-4ec8-9420-9562114d889b (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The mean (± SD) elimination half-life from plasma is 12 ± 1.3 hours; steady-state is achieved after at least three days with a 400 mg once daily regimen.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:02c29e8e-8346-4e28-b7fc-2f4cb61ad37d (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The mean (± SD) elimination half-life from plasma is 12 ± 1.3 hours; steady-state is achieved after at least three days with a 400 mg once daily regimen.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:182ecd0f-714f-42f0-9b16-fb604cf15786 (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The mean (± SD) elimination half-life from plasma is 12 ± 1.3 hours; steady-state is achieved after at least three days with a 400 mg once daily regimen.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a4e28b09-714b-46e7-b4e6-0163cad78fc5 (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The mean (± SD) elimination half-life from plasma is 12 ± 1.3 hours; steady-state is achieved after at least three days with a 400 mg once daily regimen.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:37466c79-8726-4fd6-9412-0bb83d523fe3 (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The mean (± SD) elimination half-life from plasma is 12 ± 1.3 hours; steady-state is achieved after at least three days with a 400 mg once daily regimen.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bd0c0690-ba48-41c5-b76b-b1a53c36f424 (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The mean (± SD) elimination half-life from plasma is 12 ± 1.3 hours; steady-state is achieved after at least three days with a 400 mg once daily regimen.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6067b2ee-2171-49bb-aa07-1d401ebf4f2e (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The mean (± SD) elimination half-life from plasma is 12 ± 1.3 hours; steady-state is achieved after at least three days with a 400 mg once daily regimen.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:71b02da1-3175-1db8-192a-c0a8a6cd98a5 (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The mean (± SD) elimination half-life from plasma is 12 ± 1.3 hours; steady-state is achieved after at least three days with a 400 mg once daily regimen.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1e6bc886-eec9-4cd8-be78-7563817457f2 (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The mean (± SD) elimination half-life from plasma is 12 ± 1.3 hours; steady-state is achieved after at least three days with a 400 mg once daily regimen.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:815d71cf-02de-4190-9bd1-3fdc67ef0f06 (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The mean (± SD) elimination half-life from plasma is 12 ± 1.3 hours; steady-state is achieved after at least three days with a 400 mg once daily regimen.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:371ca7b2-c62d-ef4b-3076-890b385bfff8 (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The mean (± SD) elimination half-life from plasma is 12 ± 1.3 hours; steady-state is achieved after at least three days with a 400 mg once daily regimen.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1ed191f5-7df5-488c-bb72-91ac0b618d9a (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The mean (± SD) elimination half-life from plasma is 12 ± 1.3 hours; steady-state is achieved after at least three days with a 400 mg once daily regimen.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d6789c17-4a2f-4519-9060-e3b0dba422f0 (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The mean (± SD) elimination half-life from plasma is 12 ± 1.3 hours; steady-state is achieved after at least three days with a 400 mg once daily regimen.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:be5b7a6f-9ee3-4453-807e-4761fffff60c (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The mean (± SD) elimination half-life from plasma is 12 ± 1.3 hours; steady-state is achieved after at least three days with a 400 mg once daily regimen.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f34c08e6-fe74-4de3-9e36-a82c3c1c183b (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The mean (± SD) elimination half-life from plasma is 12 ± 1.3 hours; steady-state is achieved after at least three days with a 400 mg once daily regimen.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1c6f7150-a8f4-408f-956f-c26d37030cf4 (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The mean (± SD) elimination half-life from plasma is 12 ± 1.3 hours; steady-state is achieved after at least three days with a 400 mg once daily regimen.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:18b77b31-baf3-416f-b3b7-a631c8e46d20 (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The mean (± SD) elimination half-life from plasma is 12 ± 1.3 hours; steady-state is achieved after at least three days with a 400 mg once daily regimen.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d20ba997-30de-445c-8766-924112bd834a (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The mean (± SD) elimination half-life from plasma is 12 ± 1.3 hours; steady-state is achieved after at least three days with a 400 mg once daily regimen.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c71e5987-edd7-4c38-b646-3e48a6e51bf4 (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The mean (± SD) elimination half-life from plasma is 12 ± 1.3 hours; steady-state is achieved after at least three days with a 400 mg once daily regimen.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6cd420c3-113e-4fc2-b59f-bfc7c485c14d (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The mean (± SD) elimination half-life from plasma is 12 ± 1.3 hours; steady-state is achieved after at least three days with a 400 mg once daily regimen.

    2. 13 hours

      Numeric value
      13
      Unit
      hours
      Source records
      21

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 21 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8f92f110-32d6-4d0c-a415-7a9a4cafb9b8 (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The plasma half-life of moxifloxacin was estimated to be 13 hours. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Moxifloxacin is a member of the fluoroquinolone class of anti-infective drugs [see Microbiology (12.4) ] . 12.3 Pharmacokinetics Plasma concentrations of moxifloxacin were measured in healthy adult male and female subjects who received bilateral topical ocular doses of moxifloxacin
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c38e051f-5765-4066-9953-2d0832481b1e (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The plasma half-life of moxifloxacin was estimated to be 13 hours. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Moxifloxacin is a member of the fluoroquinolone class of anti-infective drugs [see Microbiology (12.4) ]. 12.3 Pharmacokinetics Plasma concentrations of moxifloxacin were measured in healthy adult male and female subjects who received bilateral topical ocular doses of moxifloxacin 3
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1cc031d7-0766-41c0-b5b3-35119c850e23 (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The plasma half-life of moxifloxacin was estimated to be 13 hours. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Moxifloxacin is a member of the fluoroquinolone class of anti-infective drugs [ see Microbiology ( 12.4 ) ]. 12.3 Pharmacokinetics Plasma concentrations of moxifloxacin were measured in healthy adult male and female subjects who received bilateral topical ocular doses of moxifloxaci
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fc88791b-24da-48a4-85f5-93a8af3d0b51 (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The plasma half-life of moxifloxacin was estimated to be 13 hours. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Moxifloxacin is a member of the fluoroquinolone class of anti-infective drugs [see Microbiology ( 12.4 )] . 12.3 Pharmacokinetics Plasma concentrations of moxifloxacin were measured in healthy adult male and female subjects who received bilateral topical ocular doses of moxifloxacin
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f7c68d49-8c61-4bde-a880-4d78568e5aa0 (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The plasma half-life of moxifloxacin was estimated to be 13 hours. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Moxifloxacin is a member of the fluoroquinolone class of anti-infective drugs [See Microbiology (12.4)] . 12.3 Pharmacokinetics Plasma concentrations of moxifloxacin were measured in healthy adult male and female subjects who received bilateral topical ocular doses of Moxifloxacin o
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:12053b08-7e66-c6f3-e063-6394a90a9cd9 (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The plasma half-life of moxifloxacin was estimated to be 13 hours. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Moxifloxacin is a member of the fluoroquinolone class of anti-infective drugs [see Microbiology ( 12.4 )] . 12.3 Pharmacokinetics Plasma concentrations of moxifloxacin were measured in healthy adult male and female subjects who received bilateral topical ocular doses of VIGAMOX ® 3
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ca19b837-8e80-408f-af7b-b0464f20c0c3 (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The plasma half-life of moxifloxacin was estimated to be 13 hours. 12.4 Microbiology The antibacterial action of moxifloxacin results from inhibition of the topoisomerase II (DNA gyrase) and topoisomerase IV.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cdc0b0eb-5f56-45c7-b9fd-364752a95ff1 (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The plasma half-life of moxifloxacin was estimated to be 13 hours. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Moxifloxacin is a member of the fluoroquinolone class of anti-infective drugs [see Microbiology (12.4) ]. 12.3 Pharmacokinetics Plasma concentrations of moxifloxacin were measured in healthy adult male and female subjects who received bilateral topical ocular doses of moxifloxacin 3
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8f7a0c4c-34f4-7362-579b-f26c3338f792 (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The plasma half-life of moxifloxacin was estimated to be 13 hours. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Moxifloxacin is a member of the fluoroquinolone class of anti-infective drugs [ see Microbiology ( 12.4 ) ]. 12.3 Pharmacokinetics Plasma concentrations of moxifloxacin were measured in healthy adult male and female subjects who received bilateral topical ocular doses of moxifloxaci
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f9dff08a-edb2-86de-e053-6394a90a1043 (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The plasma half-life of moxifloxacin was estimated to be 13 hours. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Moxifloxacin is a member of the fluoroquinolone class of anti-infective drugs [ see Microbiology ( 12.4 ) ]. 12.3 Pharmacokinetics Plasma concentrations of moxifloxacin were measured in healthy adult male and female subjects who received bilateral topical ocular doses of moxifloxaci
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:143075b4-24d4-08a1-e063-6394a90a8a6e (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The plasma half-life of moxifloxacin was estimated to be 13 hours. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Moxifloxacin is a member of the fluoroquinolone class of anti-infective drugs [see MICROBIOLOGY ( 12.4 )] . 12.3 Pharmacokinetics Plasma concentrations of moxifloxacin were measured in healthy adult male and female subjects who received bilateral topical ocular doses of moxifloxacin
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f19fa89e-9f5d-4eed-e053-2995a90ac3ce (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The plasma half-life of moxifloxacin was estimated to be 13 hours. 12.4 Microbiology The antibacterial action of moxifloxacin results from inhibition of the topoisomerase II (DNA gyrase) and topoisomerase IV.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f702e112-b037-4e50-ac30-b1d27fc0e30e (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The plasma half-life of moxifloxacin was estimated to be 13 hours. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Moxifloxacin is a member of the fluoroquinolone class of anti-infective drugs [see Microbiology (12.4) ]. 12.3 Pharmacokinetics Plasma concentrations of moxifloxacin were measured in healthy adult male and female subjects who received bilateral topical ocular doses of moxifloxacin 3
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4dee7a26-25e2-4ce9-8fd2-e8c3ac6ef5ff (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The plasma half-life of moxifloxacin was estimated to be 13 hours. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Moxifloxacin is a member of the fluoroquinolone class of anti-infective drugs [see MICROBIOLOGY ( 12.4 )] . 12.3 Pharmacokinetics Plasma concentrations of moxifloxacin were measured in healthy adult male and female subjects who received bilateral topical ocular doses of moxifloxacin
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ae77e219-8af9-4aa4-96d3-05c9726a1d3c (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The plasma half-life of moxifloxacin was estimated to be 13 hours. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Moxifloxacin is a member of the fluoroquinolone class of anti-infective drugs [see MICROBIOLOGY ( 12.4 )] . 12.3 Pharmacokinetics Plasma concentrations of moxifloxacin were measured in healthy adult male and female subjects who received bilateral topical ocular doses of moxifloxacin
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:51d45346-5506-d2c9-e063-6394a90ae6bb (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The plasma half-life of moxifloxacin was estimated to be 13 hours. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Moxifloxacin is a member of the fluoroquinolone class of anti-infective drugs [See Microbiology (12.4)] . 12.3 Pharmacokinetics Plasma concentrations of moxifloxacin were measured in healthy adult male and female subjects who received bilateral topical ocular doses of Moxifloxacin o
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8877013d-9b49-40f7-a2c4-99bb519e104e (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The plasma half-life of moxifloxacin was estimated to be 13 hours. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Moxifloxacin is a member of the fluoroquinolone class of anti-infective drugs [see Microbiology (12.4) ]. 12.3 Pharmacokinetics Plasma concentrations of moxifloxacin were measured in healthy adult male and female subjects who received bilateral topical ocular doses of moxifloxacin 3
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:301eef74-16db-14aa-e063-6294a90ac8ff (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The plasma half-life of moxifloxacin was estimated to be 13 hours. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Moxifloxacin is a member of the fluoroquinolone class of anti-infective drugs [see MICROBIOLOGY ( 12.4 )] . 12.3 Pharmacokinetics Plasma concentrations of moxifloxacin were measured in healthy adult male and female subjects who received bilateral topical ocular doses of moxifloxacin
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4fb55f17-d9db-8148-e063-6394a90a8216 (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The plasma half-life of moxifloxacin was estimated to be 13 hours. 12.4 Microbiology The antibacterial action of moxifloxacin results from inhibition of the topoisomerase II (DNA gyrase) and topoisomerase IV.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5a5d72e2-aa39-4ead-af72-d3cabe72a5b7 (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The plasma half-life of moxifloxacin was estimated to be 13 hours. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Moxifloxacin is a member of the fluoroquinolone class of anti-infective drugs [see Microbiology (12.4) ] . 12.3 Pharmacokinetics Plasma concentrations of moxifloxacin were measured in healthy adult male and female subjects who received bilateral topical ocular doses of moxifloxacin
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d771e69b-7d9b-13fa-e053-2995a90ac161 (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The plasma half-life of moxifloxacin was estimated to be 13 hours. 12.4 Microbiology The antibacterial action of moxifloxacin results from inhibition of the topoisomerase II (DNA gyrase) and topoisomerase IV.

  5. Projected row 1045

    Medicine slug
    moxifloxacin
    Compared field
    volumeOfDistribution
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    48
    Source count
    25
    Agreement rate
    1
    Recorded readings

    1. 1.7 to 2.7 L/kg

      Numeric value
      1.7
      Unit
      L/kg
      Source records
      25

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 25 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1a98b20d-c4a1-4184-8387-a4866d1d62bf (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The volume of distribution of moxifloxacin ranges from 1.7 to 2.7 L/kg.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:54377276-96bf-4140-9e90-55623ab6b013 (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The volume of distribution of moxifloxacin ranges from 1.7 to 2.7 L/kg.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ac8a81b9-2fed-412a-8c83-db8dee1061f6 (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The volume of distribution of moxifloxacin ranges from 1.7 to 2.7 L/kg.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:45ce14e5-98b8-296b-e063-6294a90a769b (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The volume of distribution of moxifloxacin ranges from 1.7 to 2.7 L/kg.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c6fa4129-2f92-4179-ac5d-bb7b4a538789 (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The volume of distribution of moxifloxacin ranges from 1.7 to 2.7 L/kg.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:656f582c-ecba-4ec8-9420-9562114d889b (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The volume of distribution of moxifloxacin ranges from 1.7 to 2.7 L/kg.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:02c29e8e-8346-4e28-b7fc-2f4cb61ad37d (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The volume of distribution of moxifloxacin ranges from 1.7 to 2.7 L/kg.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:182ecd0f-714f-42f0-9b16-fb604cf15786 (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The volume of distribution of moxifloxacin ranges from 1.7 to 2.7 L/kg.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a4e28b09-714b-46e7-b4e6-0163cad78fc5 (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The volume of distribution of moxifloxacin ranges from 1.7 to 2.7 L/kg.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:37466c79-8726-4fd6-9412-0bb83d523fe3 (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The volume of distribution of moxifloxacin ranges from 1.7 to 2.7 L/kg.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bd0c0690-ba48-41c5-b76b-b1a53c36f424 (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The volume of distribution of moxifloxacin ranges from 1.7 to 2.7 L/kg.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6067b2ee-2171-49bb-aa07-1d401ebf4f2e (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The volume of distribution of moxifloxacin ranges from 1.7 to 2.7 L/kg.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:71b02da1-3175-1db8-192a-c0a8a6cd98a5 (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The volume of distribution of moxifloxacin ranges from 1.7 to 2.7 L/kg.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1e6bc886-eec9-4cd8-be78-7563817457f2 (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The volume of distribution of moxifloxacin ranges from 1.7 to 2.7 L/kg.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:815d71cf-02de-4190-9bd1-3fdc67ef0f06 (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The volume of distribution of moxifloxacin ranges from 1.7 to 2.7 L/kg.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:371ca7b2-c62d-ef4b-3076-890b385bfff8 (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The volume of distribution of moxifloxacin ranges from 1.7 to 2.7 L/kg.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1ed191f5-7df5-488c-bb72-91ac0b618d9a (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The volume of distribution of moxifloxacin ranges from 1.7 to 2.7 L/kg.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d6789c17-4a2f-4519-9060-e3b0dba422f0 (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The volume of distribution of moxifloxacin ranges from 1.7 to 2.7 L/kg.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:be5b7a6f-9ee3-4453-807e-4761fffff60c (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The volume of distribution of moxifloxacin ranges from 1.7 to 2.7 L/kg.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f34c08e6-fe74-4de3-9e36-a82c3c1c183b (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The volume of distribution of moxifloxacin ranges from 1.7 to 2.7 L/kg.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1c6f7150-a8f4-408f-956f-c26d37030cf4 (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The volume of distribution of moxifloxacin ranges from 1.7 to 2.7 L/kg.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:18b77b31-baf3-416f-b3b7-a631c8e46d20 (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The volume of distribution of moxifloxacin ranges from 1.7 to 2.7 L/kg.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d20ba997-30de-445c-8766-924112bd834a (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The volume of distribution of moxifloxacin ranges from 1.7 to 2.7 L/kg.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c71e5987-edd7-4c38-b646-3e48a6e51bf4 (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The volume of distribution of moxifloxacin ranges from 1.7 to 2.7 L/kg.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6cd420c3-113e-4fc2-b59f-bfc7c485c14d (opens source in a new tab)

        Moxifloxacin label

        Version not recorded · Effective date not recorded

        The volume of distribution of moxifloxacin ranges from 1.7 to 2.7 L/kg.

  6. Projected row 1046

    Medicine slug
    mycophenolate-mofetil
    Compared field
    bioavailability
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    48
    Source count
    47
    Agreement rate
    1
    Recorded readings

    1. 94%

      Numeric value
      94
      Unit
      %
      Source records
      47

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 47 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ce06afcb-4e6c-4b78-8bad-9909c8fffa52 (opens source in a new tab)

        Mycophenolate Mofetil label

        Version not recorded · Effective date not recorded

        In 12 healthy volunteers, the mean absolute bioavailability of oral MMF relative to intravenous MMF was 94%.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:32001417-130d-4c08-8e63-94ba3627ce5f (opens source in a new tab)

        Mycophenolate Mofetil label

        Version not recorded · Effective date not recorded

        In 12 healthy volunteers, the mean absolute bioavailability of oral MMF relative to intravenous MMF was 94%.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5d7f7b88-79e3-4a56-a9f3-796c28049a60 (opens source in a new tab)

        Mycophenolate Mofetil label

        Version not recorded · Effective date not recorded

        In 12 healthy volunteers, the mean absolute bioavailability of oral MMF relative to intravenous MMF was 94%.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:741e079a-646b-47ec-84ac-8e12574c2aaf (opens source in a new tab)

        Mycophenolate Mofetil label

        Version not recorded · Effective date not recorded

        In 12 healthy volunteers, the mean absolute bioavailability of oral MMF relative to intravenous MMF was 94%.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:339a10c4-e442-de9e-e063-6294a90a6208 (opens source in a new tab)

        Mycophenolate Mofetil label

        Version not recorded · Effective date not recorded

        In 12 healthy volunteers, the mean absolute bioavailability of oral MMF relative to intravenous MMF was 94%.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b414303f-e6f3-4e22-a537-96be352b59a4 (opens source in a new tab)

        Mycophenolate Mofetil label

        Version not recorded · Effective date not recorded

        In 12 healthy volunteers, the mean absolute bioavailability of oral MMF relative to intravenous MMF was 94%.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:84c6f6bb-8924-4da5-9629-126197195f83 (opens source in a new tab)

        Mycophenolate Mofetil label

        Version not recorded · Effective date not recorded

        In 12 healthy volunteers, the mean absolute bioavailability of oral MMF relative to intravenous MMF was 94%.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8015f042-54fb-4a7a-a10b-6219e1a450c8 (opens source in a new tab)

        Mycophenolate Mofetil label

        Version not recorded · Effective date not recorded

        In 12 healthy volunteers, the mean absolute bioavailability of oral MMF relative to intravenous MMF was 94%.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d9af72d6-7b3e-4c08-94b9-1d8b499cb7f9 (opens source in a new tab)

        Mycophenolate Mofetil label

        Version not recorded · Effective date not recorded

        In 12 healthy volunteers, the mean absolute bioavailability of oral MMF relative to intravenous MMF was 94%.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:838449b3-4397-4e35-b9b9-683f5a48bff2 (opens source in a new tab)

        Mycophenolate Mofetil label

        Version not recorded · Effective date not recorded

        In 12 healthy volunteers, the mean absolute bioavailability of oral MMF relative to intravenous MMF was 94%.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:461a252f-ff81-4e08-b256-a497b14835fa (opens source in a new tab)

        Mycophenolate Mofetil label

        Version not recorded · Effective date not recorded

        In 12 healthy volunteers, the mean absolute bioavailability of oral MMF relative to intravenous MMF was 94%.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:21ff53b0-b4ba-4473-91e4-76ef41681064 (opens source in a new tab)

        Mycophenolate Mofetil label

        Version not recorded · Effective date not recorded

        In 12 healthy volunteers, the mean absolute bioavailability of oral MMF relative to intravenous MMF was 94%.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fbbe6521-0e21-5372-e053-6394a90ae5e4 (opens source in a new tab)

        Mycophenolate Mofetil label

        Version not recorded · Effective date not recorded

        In 12 healthy volunteers, the mean absolute bioavailability of oral MMF relative to intravenous MMF was 94%.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d176199c-dc3f-48c8-b7d2-c5d0a6a242fe (opens source in a new tab)

        Mycophenolate Mofetil label

        Version not recorded · Effective date not recorded

        In 12 healthy volunteers, the mean absolute bioavailability of oral MMF relative to intravenous MMF was 94%.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:da02b428-42a4-4007-b0b7-695f2db010f2 (opens source in a new tab)

        Mycophenolate Mofetil label

        Version not recorded · Effective date not recorded

        In 12 healthy volunteers, the mean absolute bioavailability of oral MMF relative to intravenous MMF was 94%.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:df3ba2e9-00bb-40af-8658-2c5fd2e398ef (opens source in a new tab)

        Mycophenolate Mofetil label

        Version not recorded · Effective date not recorded

        In 12 healthy volunteers, the mean absolute bioavailability of oral MMF relative to intravenous MMF was 94%.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0f1704e2-a66a-4be5-8127-ebb5947c7b64 (opens source in a new tab)

        Mycophenolate Mofetil label

        Version not recorded · Effective date not recorded

        In 12 healthy volunteers, the mean absolute bioavailability of oral MMF relative to intravenous MMF was 94%.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d203775c-bf36-460c-bacf-3ab2348a514f (opens source in a new tab)

        Mycophenolate Mofetil label

        Version not recorded · Effective date not recorded

        In 12 healthy volunteers, the mean absolute bioavailability of oral MMF relative to intravenous MMF was 94%.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6abc5727-ee8e-43ad-ab39-0eef2feb257a (opens source in a new tab)

        Mycophenolate Mofetil label

        Version not recorded · Effective date not recorded

        In 12 healthy volunteers, the mean absolute bioavailability of oral MMF relative to intravenous MMF was 94%.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:27fd9381-8d82-4187-897f-98f41f94e90f (opens source in a new tab)

        Mycophenolate Mofetil label

        Version not recorded · Effective date not recorded

        In 12 healthy volunteers, the mean absolute bioavailability of oral MMF relative to intravenous MMF was 94%.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b4170ad9-67f0-42ea-b694-6b80824a607a (opens source in a new tab)

        Mycophenolate Mofetil label

        Version not recorded · Effective date not recorded

        In 12 healthy volunteers, the mean absolute bioavailability of oral MMF relative to intravenous MMF was 94%.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2b9ae8ff-f2bc-ccef-e063-6294a90a76da (opens source in a new tab)

        Mycophenolate Mofetil label

        Version not recorded · Effective date not recorded

        In 12 healthy volunteers, the mean absolute bioavailability of oral MMF relative to intravenous MMF was 94%.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:afb59492-2bb1-4cf1-af4b-a5020b56c124 (opens source in a new tab)

        Mycophenolate Mofetil label

        Version not recorded · Effective date not recorded

        In 12 healthy volunteers, the mean absolute bioavailability of oral MMF relative to intravenous MMF was 94%.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:64ac00ee-298c-49cf-a91c-78019a0d014d (opens source in a new tab)

        Mycophenolate Mofetil label

        Version not recorded · Effective date not recorded

        In 12 healthy volunteers, the mean absolute bioavailability of oral MMF relative to intravenous MMF was 94%.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ca633c6a-1e58-4faa-8e5d-71f89cefaa01 (opens source in a new tab)

        Mycophenolate Mofetil label

        Version not recorded · Effective date not recorded

        In 12 healthy volunteers, the mean absolute bioavailability of oral MMF relative to intravenous MMF was 94%.
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f2eafcbb-77ab-461e-aa09-9cc4123eb3bd (opens source in a new tab)

        Mycophenolate Mofetil label

        Version not recorded · Effective date not recorded

        In 12 healthy volunteers, the mean absolute bioavailability of oral MMF relative to intravenous MMF was 94%.
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b41cca9f-0922-4171-8d1b-8e0d32ae1cc1 (opens source in a new tab)

        Mycophenolate Mofetil label

        Version not recorded · Effective date not recorded

        In 12 healthy volunteers, the mean absolute bioavailability of oral MMF relative to intravenous MMF was 94%.
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:35ba0428-e267-49a5-99a9-c58853f7989d (opens source in a new tab)

        Mycophenolate Mofetil label

        Version not recorded · Effective date not recorded

        In 12 healthy volunteers, the mean absolute bioavailability of oral MMF relative to intravenous MMF was 94%.
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:75a76397-bb62-4014-8488-949a711b25f0 (opens source in a new tab)

        Mycophenolate Mofetil label

        Version not recorded · Effective date not recorded

        In 12 healthy volunteers, the mean absolute bioavailability of oral MMF relative to intravenous MMF was 94%.
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:118e9bc8-c1a9-41d0-89e6-251f3be0b99c (opens source in a new tab)

        Mycophenolate Mofetil label

        Version not recorded · Effective date not recorded

        In 12 healthy volunteers, the mean absolute bioavailability of oral MMF relative to intravenous MMF was 94%.
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3eb584dc-f72d-4545-96fa-ab3d47be41ce (opens source in a new tab)

        Mycophenolate Mofetil label

        Version not recorded · Effective date not recorded

        In 12 healthy volunteers, the mean absolute bioavailability of oral MMF relative to intravenous MMF was 94%.
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:99b2eb58-8d14-48fc-bbe1-aacb711a783e (opens source in a new tab)

        Mycophenolate Mofetil label

        Version not recorded · Effective date not recorded

        In 12 healthy volunteers, the mean absolute bioavailability of oral MMF relative to intravenous MMF was 94%.
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:32dd890a-cfe3-4129-bce6-1d3dbe38e4f3 (opens source in a new tab)

        Mycophenolate Mofetil label

        Version not recorded · Effective date not recorded

        In 12 healthy volunteers, the mean absolute bioavailability of oral MMF relative to intravenous MMF was 94%.
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:175d8b87-e06a-4c9e-b3de-378114b52274 (opens source in a new tab)

        Mycophenolate Mofetil label

        Version not recorded · Effective date not recorded

        In 12 healthy volunteers, the mean absolute bioavailability of oral MMF relative to intravenous MMF was 94%.
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:24c0b94a-c141-44b6-a6f0-ade1669b254c (opens source in a new tab)

        Mycophenolate Mofetil label

        Version not recorded · Effective date not recorded

        In 12 healthy volunteers, the mean absolute bioavailability of oral MMF relative to intravenous MMF was 94%.
      36. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9650af9b-d36f-4a2f-9647-d0f798933402 (opens source in a new tab)

        Mycophenolate Mofetil label

        Version not recorded · Effective date not recorded

        In 12 healthy volunteers, the mean absolute bioavailability of oral MMF relative to intravenous MMF was 94%.
      37. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9f84ea84-2d8b-4d91-a33f-7dfb5df937dc (opens source in a new tab)

        Mycophenolate Mofetil label

        Version not recorded · Effective date not recorded

        In 12 healthy volunteers, the mean absolute bioavailability of oral MMF relative to intravenous MMF was 94%.
      38. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8faf357b-99a1-440b-8eac-8545cb19a69c (opens source in a new tab)

        Mycophenolate Mofetil label

        Version not recorded · Effective date not recorded

        In 12 healthy volunteers, the mean absolute bioavailability of oral MMF relative to intravenous MMF was 94%.
      39. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:20fa7709-a203-481f-aaf4-e98fab1acd0d (opens source in a new tab)

        Mycophenolate Mofetil label

        Version not recorded · Effective date not recorded

        In 12 healthy volunteers, the mean absolute bioavailability of oral MMF relative to intravenous MMF was 94%.
      40. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a15c26d8-5a27-48ba-a669-8546803d901f (opens source in a new tab)

        Mycophenolate Mofetil label

        Version not recorded · Effective date not recorded

        In 12 healthy volunteers, the mean absolute bioavailability of oral MMF relative to intravenous MMF was 94%.
      41. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3ac54299-15cc-4c7a-8831-60c15a859b85 (opens source in a new tab)

        Mycophenolate Mofetil label

        Version not recorded · Effective date not recorded

        In 12 healthy volunteers, the mean absolute bioavailability of oral MMF relative to intravenous MMF was 94%.
      42. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:77a75d5b-a90d-4ee5-aa8a-6da97d130357 (opens source in a new tab)

        Mycophenolate Mofetil label

        Version not recorded · Effective date not recorded

        In 12 healthy volunteers, the mean absolute bioavailability of oral MMF relative to intravenous MMF was 94%.
      43. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c3ded171-89da-4644-9ee8-dbcf6258036f (opens source in a new tab)

        Mycophenolate Mofetil label

        Version not recorded · Effective date not recorded

        In 12 healthy volunteers, the mean absolute bioavailability of oral MMF relative to intravenous MMF was 94%.
      44. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ffcc237c-f31b-77b8-e053-6294a90a603e (opens source in a new tab)

        Mycophenolate Mofetil label

        Version not recorded · Effective date not recorded

        In 12 healthy volunteers, the mean absolute bioavailability of oral MMF relative to intravenous MMF was 94%.
      45. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:127eabe2-8386-452a-ad6b-d879e1f2c099 (opens source in a new tab)

        Mycophenolate Mofetil label

        Version not recorded · Effective date not recorded

        In 12 healthy volunteers, the mean absolute bioavailability of oral MMF relative to intravenous MMF was 94%.
      46. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e94895d9-f040-4a75-9f04-9814238b8f3c (opens source in a new tab)

        Mycophenolate Mofetil label

        Version not recorded · Effective date not recorded

        In 12 healthy volunteers, the mean absolute bioavailability of oral MMF relative to intravenous MMF was 94%.
      47. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:37241e87-4af4-4dc3-a1aa-ea6f20d8dc40 (opens source in a new tab)

        Mycophenolate Mofetil label

        Version not recorded · Effective date not recorded

        In 12 healthy volunteers, the mean absolute bioavailability of oral MMF relative to intravenous MMF was 94%.

  7. Projected row 1047

    Medicine slug
    mycophenolic-acid
    Compared field
    halfLife
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    20
    Source count
    20
    Agreement rate
    0.95
    Recorded readings

    1. 16 hours

      Numeric value
      16
      Unit
      hours
      Source records
      19

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 19 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f7c05bf9-816f-41e6-999d-bb3c7abd2627 (opens source in a new tab)

        Mycophenolic Acid label

        Version not recorded · Effective date not recorded

        The mean elimination half-life of MPA and MPAG ranged between 8 and 16 hours, and 13 and 17 hours, respectively.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8516e135-5cc0-ef2d-6dad-0f9f841bb27b (opens source in a new tab)

        Mycophenolic Acid label

        Version not recorded · Effective date not recorded

        The mean elimination half-life of MPA and MPAG ranged between 8 and 16 hours, and 13 and 17 hours, respectively.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dc24aa15-330c-4698-872f-159d7e582b4b (opens source in a new tab)

        Mycophenolic Acid label

        Version not recorded · Effective date not recorded

        The mean elimination half-life of MPA and MPAG ranged between 8 and 16 hours, and 13 and 17 hours, respectively.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bc38bc5e-7f0a-4419-81ec-04726ce47421 (opens source in a new tab)

        Mycophenolic Acid label

        Version not recorded · Effective date not recorded

        The mean elimination half-life of MPA and MPAG ranged between 8 and 16 hours, and 13 and 17 hours, respectively.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a2c1a135-67e7-4052-bbb9-b6135d45ff75 (opens source in a new tab)

        Mycophenolic Acid label

        Version not recorded · Effective date not recorded

        The mean elimination half-life of MPA and MPAG ranged between 8 and 16 hours, and 13 and 17 hours, respectively.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:93763b39-ba21-449b-bdc5-254ba57154e4 (opens source in a new tab)

        Mycophenolic Acid label

        Version not recorded · Effective date not recorded

        The mean elimination half-life of MPA and MPAG ranged between 8 and 16 hours, and 13 and 17 hours, respectively.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c0efafa6-d249-f44a-fbf3-e6bd3acaf6f0 (opens source in a new tab)

        Mycophenolic Acid label

        Version not recorded · Effective date not recorded

        The mean elimination half-life of MPA and MPAG ranged between 8 and 16 hours, and 13 and 17 hours, respectively.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8b73dc87-c611-4bcb-8852-532eb388cb2e (opens source in a new tab)

        Mycophenolic Acid label

        Version not recorded · Effective date not recorded

        The mean elimination half-life of MPA and MPAG ranged between 8 and 16 hours, and 13 and 17 hours, respectively.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c1ce92ef-4102-1487-e053-2995a90ac521 (opens source in a new tab)

        Mycophenolic Acid label

        Version not recorded · Effective date not recorded

        The mean elimination half-life of MPA and MPAG ranged between 8 and 16 hours, and 13 and 17 hours, respectively.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6b170816-6e5c-400c-b97b-82bbbb7d4925 (opens source in a new tab)

        Mycophenolic Acid label

        Version not recorded · Effective date not recorded

        The mean elimination half-life of MPA and MPAG ranged between 8 and 16 hours, and 13 and 17 hours, respectively.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8617bd03-6da7-48ca-b430-6dfc38f19e2b (opens source in a new tab)

        Mycophenolic Acid label

        Version not recorded · Effective date not recorded

        The mean elimination half-life of MPA and MPAG ranged between 8 and 16 hours, and 13 and 17 hours, respectively.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3a0a6ef4-fb2c-47be-82d7-d2675059c45b (opens source in a new tab)

        Mycophenolic Acid label

        Version not recorded · Effective date not recorded

        The mean elimination half-life of MPA and MPAG ranged between 8 and 16 hours, and 13 and 17 hours, respectively.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bc98d9a1-b4e3-4085-a8ba-d3313246658a (opens source in a new tab)

        Mycophenolic Acid label

        Version not recorded · Effective date not recorded

        The mean elimination half-life of MPA and MPAG ranged between 8 and 16 hours, and 13 and 17 hours, respectively.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7f8d259a-9880-bb8b-2738-b3c6c1edf152 (opens source in a new tab)

        Mycophenolic Acid label

        Version not recorded · Effective date not recorded

        The mean elimination half-life of MPA and MPAG ranged between 8 and 16 hours, and 13 and 17 hours, respectively.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5b224d7f-fecb-4531-9d27-008347777c9d (opens source in a new tab)

        Mycophenolic Acid label

        Version not recorded · Effective date not recorded

        The mean elimination half-life of MPA and MPAG ranged between 8 and 16 hours, and 13 and 17 hours, respectively.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2d9975e1-baee-4b0c-83de-8a0a92c5d075 (opens source in a new tab)

        Mycophenolic Acid label

        Version not recorded · Effective date not recorded

        The mean elimination half-life of MPA and MPAG ranged between 8 and 16 hours, and 13 and 17 hours, respectively.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:26b31126-4262-4a15-8a16-234c86763176 (opens source in a new tab)

        Mycophenolic Acid label

        Version not recorded · Effective date not recorded

        The mean elimination half-life of MPA and MPAG ranged between 8 and 16 hours, and 13 and 17 hours, respectively.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:eed26501-890d-4ff6-88e7-6dbea4726e53 (opens source in a new tab)

        Mycophenolic Acid label

        Version not recorded · Effective date not recorded

        The mean elimination half-life of MPA and MPAG ranged between 8 and 16 hours, and 13 and 17 hours, respectively.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a374549e-8afd-48fe-ae3f-368984689a2a (opens source in a new tab)

        Mycophenolic Acid label

        Version not recorded · Effective date not recorded

        The mean elimination half-life of MPA and MPAG ranged between 8 and 16 hours, and 13 and 17 hours, respectively.

    2. 8 hours

      Numeric value
      8
      Unit
      hours
      Source records
      1

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 1 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cbc3e916-09e2-4e6e-9e5e-98375f5e6d41 (opens source in a new tab)

        Mycophenolic Acid label

        Version not recorded · Effective date not recorded

        The mean elimination half-life of MPA and MPAG ranged between 8 hours and 16 hours, and 13 hours and 17 hours, respectively.

  8. Projected row 1048

    Medicine slug
    mycophenolic-acid
    Compared field
    proteinBinding
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    20
    Source count
    20
    Agreement rate
    1
    Recorded readings

    1. 82%

      Numeric value
      82
      Unit
      %
      Source records
      20

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 20 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f7c05bf9-816f-41e6-999d-bb3c7abd2627 (opens source in a new tab)

        Mycophenolic Acid label

        Version not recorded · Effective date not recorded

        The protein binding of MPAG is 82%.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8516e135-5cc0-ef2d-6dad-0f9f841bb27b (opens source in a new tab)

        Mycophenolic Acid label

        Version not recorded · Effective date not recorded

        The protein binding of MPAG is 82%.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dc24aa15-330c-4698-872f-159d7e582b4b (opens source in a new tab)

        Mycophenolic Acid label

        Version not recorded · Effective date not recorded

        The protein binding of MPAG is 82%.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bc38bc5e-7f0a-4419-81ec-04726ce47421 (opens source in a new tab)

        Mycophenolic Acid label

        Version not recorded · Effective date not recorded

        The protein binding of MPAG is 82%.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a2c1a135-67e7-4052-bbb9-b6135d45ff75 (opens source in a new tab)

        Mycophenolic Acid label

        Version not recorded · Effective date not recorded

        The protein binding of MPAG is 82%.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:93763b39-ba21-449b-bdc5-254ba57154e4 (opens source in a new tab)

        Mycophenolic Acid label

        Version not recorded · Effective date not recorded

        The protein binding of MPAG is 82%.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c0efafa6-d249-f44a-fbf3-e6bd3acaf6f0 (opens source in a new tab)

        Mycophenolic Acid label

        Version not recorded · Effective date not recorded

        The protein binding of MPAG is 82%.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8b73dc87-c611-4bcb-8852-532eb388cb2e (opens source in a new tab)

        Mycophenolic Acid label

        Version not recorded · Effective date not recorded

        The protein binding of MPAG is 82%.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c1ce92ef-4102-1487-e053-2995a90ac521 (opens source in a new tab)

        Mycophenolic Acid label

        Version not recorded · Effective date not recorded

        The protein binding of MPAG is 82%.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6b170816-6e5c-400c-b97b-82bbbb7d4925 (opens source in a new tab)

        Mycophenolic Acid label

        Version not recorded · Effective date not recorded

        The protein binding of MPAG is 82%.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8617bd03-6da7-48ca-b430-6dfc38f19e2b (opens source in a new tab)

        Mycophenolic Acid label

        Version not recorded · Effective date not recorded

        The protein binding of MPAG is 82%.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cbc3e916-09e2-4e6e-9e5e-98375f5e6d41 (opens source in a new tab)

        Mycophenolic Acid label

        Version not recorded · Effective date not recorded

        The protein binding of MPAG is 82%.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3a0a6ef4-fb2c-47be-82d7-d2675059c45b (opens source in a new tab)

        Mycophenolic Acid label

        Version not recorded · Effective date not recorded

        The protein binding of MPAG is 82%.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bc98d9a1-b4e3-4085-a8ba-d3313246658a (opens source in a new tab)

        Mycophenolic Acid label

        Version not recorded · Effective date not recorded

        The protein binding of MPAG is 82%.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7f8d259a-9880-bb8b-2738-b3c6c1edf152 (opens source in a new tab)

        Mycophenolic Acid label

        Version not recorded · Effective date not recorded

        The protein binding of MPAG is 82%.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5b224d7f-fecb-4531-9d27-008347777c9d (opens source in a new tab)

        Mycophenolic Acid label

        Version not recorded · Effective date not recorded

        The protein binding of MPAG is 82%.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2d9975e1-baee-4b0c-83de-8a0a92c5d075 (opens source in a new tab)

        Mycophenolic Acid label

        Version not recorded · Effective date not recorded

        The protein binding of MPAG is 82%.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:26b31126-4262-4a15-8a16-234c86763176 (opens source in a new tab)

        Mycophenolic Acid label

        Version not recorded · Effective date not recorded

        The protein binding of MPAG is 82%.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:eed26501-890d-4ff6-88e7-6dbea4726e53 (opens source in a new tab)

        Mycophenolic Acid label

        Version not recorded · Effective date not recorded

        The protein binding of MPAG is 82%.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a374549e-8afd-48fe-ae3f-368984689a2a (opens source in a new tab)

        Mycophenolic Acid label

        Version not recorded · Effective date not recorded

        The protein binding of MPAG is 82%.

  9. Projected row 1049

    Medicine slug
    nabumetone
    Compared field
    halfLife
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    50
    Source count
    50
    Agreement rate
    1
    Recorded readings

    1. 24 hours

      Numeric value
      24
      Unit
      hours
      Source records
      50

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 50 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:da34003b-81a4-2efd-e053-2995a90a961c (opens source in a new tab)

        Nabumetone label

        Version not recorded · Effective date not recorded

        ites 34% Total % Dose: 73% Following oral administration of dosages of 1,000 mg to 2,000 mg to steady state, the mean plasma clearance of 6MNA is 20 to 30 mL/min and the elimination half-life is approximately 24 hours.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:da259c7c-6f1e-403c-b42b-596d53b61fe5 (opens source in a new tab)

        Nabumetone label

        Version not recorded · Effective date not recorded

        ites 34% Total % Dose: 73% Following oral administration of dosages of 1,000 mg to 2,000 mg to steady state, the mean plasma clearance of 6MNA is 20 to 30 mL/min and the elimination half-life is approximately 24 hours.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f4392863-ed3f-4fbd-8260-49827609aa2e (opens source in a new tab)

        Nabumetone label

        Version not recorded · Effective date not recorded

        ites 34% Total % Dose: 73% Following oral administration of dosages of 1,000 mg to 2,000 mg to steady state, the mean plasma clearance of 6MNA is 20 to 30 mL/min and the elimination half-life is approximately 24 hours.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:af9969df-ce14-c0bc-e053-2995a90a3f59 (opens source in a new tab)

        Nabumetone label

        Version not recorded · Effective date not recorded

        ites 34% Total % Dose: 73% Following oral administration of dosages of 1,000 mg to 2,000 mg to steady state, the mean plasma clearance of 6MNA is 20 to 30 mL/min and the elimination half-life is approximately 24 hours.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:53656d70-6572-4669-6465-6c6973555341 (opens source in a new tab)

        Nabumetone label

        Version not recorded · Effective date not recorded

        ites 34% Total % Dose: 73% Following oral administration of dosages of 1,000 mg to 2,000 mg to steady state, the mean plasma clearance of 6MNA is 20 to 30 mL/min and the elimination half-life is approximately 24 hours.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:75c51686-9c5e-4c13-acf4-2d04502eedda (opens source in a new tab)

        Nabumetone label

        Version not recorded · Effective date not recorded

        ites 34% Total % Dose: 73% Following oral administration of dosages of 1,000 mg to 2,000 mg to steady state, the mean plasma clearance of 6MNA is 20 to 30 mL/min and the elimination half-life is approximately 24 hours.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b2a41c0b-e2ad-4e14-a2f7-2049c12c35da (opens source in a new tab)

        Nabumetone label

        Version not recorded · Effective date not recorded

        ites 34% Total % Dose: 73% Following oral administration of dosages of 1,000 mg to 2,000 mg to steady state, the mean plasma clearance of 6MNA is 20 to 30 mL/min and the elimination half-life is approximately 24 hours.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a4553637-498e-491a-982a-cff81b43aa6c (opens source in a new tab)

        Nabumetone label

        Version not recorded · Effective date not recorded

        ites 34% Total % Dose: 73% Following oral administration of dosages of 1,000 mg to 2,000 mg to steady state, the mean plasma clearance of 6MNA is 20 to 30 mL/min and the elimination half-life is approximately 24 hours.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:94930125-b792-579e-e053-2995a90ab6f9 (opens source in a new tab)

        Nabumetone label

        Version not recorded · Effective date not recorded

        ites 34% Total % Dose: 73% Following oral administration of dosages of 1,000 mg to 2,000 mg to steady state, the mean plasma clearance of 6MNA is 20 to 30 mL/min and the elimination half-life is approximately 24 hours.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:95aa8124-08fe-ff2f-e053-2a95a90a3c8f (opens source in a new tab)

        Nabumetone label

        Version not recorded · Effective date not recorded

        ites 34% Total % Dose: 73% Following oral administration of dosages of 1,000 mg to 2,000 mg to steady state, the mean plasma clearance of 6MNA is 20 to 30 mL/min and the elimination half-life is approximately 24 hours.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e87289f4-d4f9-4510-aaa5-51f8f8167658 (opens source in a new tab)

        Nabumetone label

        Version not recorded · Effective date not recorded

        ites 34% Total % Dose: 73% Following oral administration of dosages of 1,000 mg to 2,000 mg to steady state, the mean plasma clearance of 6MNA is 20 to 30 mL/min and the elimination half-life is approximately 24 hours.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0653b873-b74b-4ec6-b112-675760703d91 (opens source in a new tab)

        Nabumetone label

        Version not recorded · Effective date not recorded

        ites 34% Total % Dose: 73% Following oral administration of dosages of 1,000 mg to 2,000 mg to steady state, the mean plasma clearance of 6MNA is 20 to 30 mL/min and the elimination half-life is approximately 24 hours.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:84bb2887-bab4-46ae-a07c-fa2a32c04b50 (opens source in a new tab)

        Nabumetone label

        Version not recorded · Effective date not recorded

        Total % Dose: 73% Following oral administration of dosages of 1,000 mg to 2,000 mg to steady state, the mean plasma clearance of 6MNA is 20 mL/min to 30 mL/min. and the elimination half-life is approximately 24 hours. image description Elderly Patients Steady-state plasma concentrations in elderly patients were generally higher than in young healthy subjects.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7a1643bf-6627-4b12-8246-6acc40517cf2 (opens source in a new tab)

        Nabumetone label

        Version not recorded · Effective date not recorded

        ites 34% Total % Dose: 73% Following oral administration of dosages of 1,000 mg to 2,000 mg to steady state, the mean plasma clearance of 6MNA is 20 to 30 mL/min and the elimination half-life is approximately 24 hours.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:af9994ac-6687-2df2-e053-2995a90a959a (opens source in a new tab)

        Nabumetone label

        Version not recorded · Effective date not recorded

        ites 34% Total % Dose: 73% Following oral administration of dosages of 1,000 mg to 2,000 mg to steady state, the mean plasma clearance of 6MNA is 20 to 30 mL/min and the elimination half-life is approximately 24 hours.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a8600b12-f180-0b27-e053-2995a90acbd9 (opens source in a new tab)

        Nabumetone label

        Version not recorded · Effective date not recorded

        ites 34% Total % Dose: 73% Following oral administration of dosages of 1,000 mg to 2,000 mg to steady state, the mean plasma clearance of 6MNA is 20 to 30 mL/min and the elimination half-life is approximately 24 hours.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:69620c53-b37a-45b9-b560-221bbcd98fda (opens source in a new tab)

        Nabumetone label

        Version not recorded · Effective date not recorded

        ites 34% Total % Dose: 73% Following oral administration of dosages of 1,000 mg to 2,000 mg to steady state, the mean plasma clearance of 6MNA is 20 to 30 mL/min and the elimination half-life is approximately 24 hours.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ad9f2a34-6244-49b7-98ee-af18cb55693c (opens source in a new tab)

        Nabumetone label

        Version not recorded · Effective date not recorded

        ites 34% Total % Dose: 73% Following oral administration of dosages of 1,000 mg to 2,000 mg to steady state, the mean plasma clearance of 6MNA is 20 to 30 mL/min and the elimination half-life is approximately 24 hours.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:311ae656-55d2-4116-a1bd-6f4a4ce70185 (opens source in a new tab)

        Nabumetone label

        Version not recorded · Effective date not recorded

        ites 34% Total % Dose: 73% Following oral administration of dosages of 1,000 mg to 2,000 mg to steady state, the mean plasma clearance of 6MNA is 20 to 30 mL/min and the elimination half-life is approximately 24 hours.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d997d125-dfc5-4cc5-b7a6-03f5a7248d14 (opens source in a new tab)

        Nabumetone label

        Version not recorded · Effective date not recorded

        ites 34% Total % Dose: 73% Following oral administration of dosages of 1,000 mg to 2,000 mg to steady state, the mean plasma clearance of 6MNA is 20 to 30 mL/min and the elimination half-life is approximately 24 hours.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:80c6888d-03b4-44f3-b94d-bcf5154ceae5 (opens source in a new tab)

        Nabumetone label

        Version not recorded · Effective date not recorded

        ites 34% Total % Dose: 73% Following oral administration of dosages of 1,000 mg to 2,000 mg to steady state, the mean plasma clearance of 6MNA is 20 to 30 mL/min and the elimination half-life is approximately 24 hours.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8f3c1b1d-2765-4cb5-92df-044b99339c92 (opens source in a new tab)

        Nabumetone label

        Version not recorded · Effective date not recorded

        ites 34% Total % Dose: 73% Following oral administration of dosages of 1,000 mg to 2,000 mg to steady state, the mean plasma clearance of 6MNA is 20 to 30 mL/min and the elimination half-life is approximately 24 hours.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a9a0af85-6c43-4a2d-ba75-0be4ca64c931 (opens source in a new tab)

        Nabumetone label

        Version not recorded · Effective date not recorded

        tes 34% Total % Dose: 73 % Following oral administration of dosages of 1,000 mg to 2,000 mg to steady state, the mean plasma clearance of 6MNA is 20 to 30 mL/min and the elimination half-life is approximately 24 hours.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:06f73fa8-7a8f-4160-939e-a25980a11906 (opens source in a new tab)

        Nabumetone label

        Version not recorded · Effective date not recorded

        ites 34% Total % Dose: 73% Following oral administration of dosages of 1,000 mg to 2,000 mg to steady state, the mean plasma clearance of 6MNA is 20 to 30 mL/min and the elimination half-life is approximately 24 hours.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dd0d2652-d335-45db-af43-5a2523f7299a (opens source in a new tab)

        Nabumetone label

        Version not recorded · Effective date not recorded

        ites 34% Total % Dose: 73% Following oral administration of dosages of 1,000 mg to 2,000 mg to steady state, the mean plasma clearance of 6MNA is 20 to 30 mL/min and the elimination half-life is approximately 24 hours.
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cf96d189-5417-4181-a5fb-169b269560a2 (opens source in a new tab)

        Nabumetone label

        Version not recorded · Effective date not recorded

        ites 34% Total % Dose: 73% Following oral administration of dosages of 1,000 mg to 2,000 mg to steady state, the mean plasma clearance of 6MNA is 20 to 30 mL/min and the elimination half-life is approximately 24 hours.
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:62f2e0bf-e5c8-480c-ac5e-401ced3bbc67 (opens source in a new tab)

        Nabumetone label

        Version not recorded · Effective date not recorded

        ites 34% Total % Dose: 73% Following oral administration of dosages of 1,000 mg to 2,000 mg to steady state, the mean plasma clearance of 6MNA is 20 to 30 mL/min and the elimination half-life is approximately 24 hours.
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5ba602e9-846e-42b3-9ea6-fb461a948947 (opens source in a new tab)

        Nabumetone label

        Version not recorded · Effective date not recorded

        ites 34% Total % Dose: 73% Following oral administration of dosages of 1,000 mg to 2,000 mg to steady state, the mean plasma clearance of 6MNA is 20 to 30 mL/min and the elimination half-life is approximately 24 hours.
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0186328f-3eb7-4407-bf9e-8007d08ebe7b (opens source in a new tab)

        Nabumetone label

        Version not recorded · Effective date not recorded

        ites 34% Total % Dose: 73% Following oral administration of dosages of 1,000 mg to 2,000 mg to steady state, the mean plasma clearance of 6MNA is 20 to 30 mL/min and the elimination half-life is approximately 24 hours.
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b088f564-43ff-8007-e053-2995a90ab012 (opens source in a new tab)

        Nabumetone label

        Version not recorded · Effective date not recorded

        ites 34% Total % Dose: 73% Following oral administration of dosages of 1,000 mg to 2,000 mg to steady state, the mean plasma clearance of 6MNA is 20 to 30 mL/min and the elimination half-life is approximately 24 hours.
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:95769e02-fa4a-4389-a2fa-3146eae02526 (opens source in a new tab)

        Nabumetone label

        Version not recorded · Effective date not recorded

        ites 34% Total % Dose: 73% Following oral administration of dosages of 1,000 mg to 2,000 mg to steady state, the mean plasma clearance of 6MNA is 20 to 30 mL/min and the elimination half-life is approximately 24 hours.
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:55e733f0-7633-4412-b5a3-07d9363bbd71 (opens source in a new tab)

        Nabumetone label

        Version not recorded · Effective date not recorded

        ites 34% Total % Dose: 73% Following oral administration of dosages of 1,000 mg to 2,000 mg to steady state, the mean plasma clearance of 6MNA is 20 to 30 mL/min and the elimination half-life is approximately 24 hours.
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ef7c3da8-797f-4ea9-8999-53509785a0f7 (opens source in a new tab)

        Nabumetone label

        Version not recorded · Effective date not recorded

        ites 34% Total % Dose: 73% Following oral administration of dosages of 1,000 mg to 2,000 mg to steady state, the mean plasma clearance of 6MNA is 20 to 30 mL/min and the elimination half-life is approximately 24 hours.
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6106afa3-e138-4b4d-8c13-992bf5062097 (opens source in a new tab)

        Nabumetone label

        Version not recorded · Effective date not recorded

        ites 34% Total % Dose: 73% Following oral administration of dosages of 1,000 mg to 2,000 mg to steady state, the mean plasma clearance of 6MNA is 20 to 30 mL/min and the elimination half-life is approximately 24 hours.
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:455c9992-39a0-4353-a121-57e700c77942 (opens source in a new tab)

        Nabumetone label

        Version not recorded · Effective date not recorded

        ites 34% Total % Dose: 73% Following oral administration of dosages of 1,000 mg to 2,000 mg to steady state, the mean plasma clearance of 6MNA is 20 to 30 mL/min and the elimination half-life is approximately 24 hours.
      36. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:85954380-a520-46d7-89ac-e4b19d6e00a1 (opens source in a new tab)

        Nabumetone label

        Version not recorded · Effective date not recorded

        ites 34% Total % Dose: 73% Following oral administration of dosages of 1,000 mg to 2,000 mg to steady state, the mean plasma clearance of 6MNA is 20 to 30 mL/min and the elimination half-life is approximately 24 hours.
      37. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b43db4aa-6013-3942-e053-2a95a90a5189 (opens source in a new tab)

        Nabumetone label

        Version not recorded · Effective date not recorded

        ites 34% Total % Dose: 73% Following oral administration of dosages of 1,000 mg to 2,000 mg to steady state, the mean plasma clearance of 6MNA is 20 to 30 mL/min and the elimination half-life is approximately 24 hours.
      38. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5a66c21f-4f06-4fb8-98fa-e81949586afd (opens source in a new tab)

        Nabumetone label

        Version not recorded · Effective date not recorded

        ites 34% Total % Dose: 73% Following oral administration of dosages of 1,000 mg to 2,000 mg to steady state, the mean plasma clearance of 6MNA is 20 to 30 mL/min and the elimination half-life is approximately 24 hours.
      39. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:04a71deb-2c9d-436c-a574-e5991b6a5248 (opens source in a new tab)

        Nabumetone label

        Version not recorded · Effective date not recorded

        ites 34% Total % Dose: 73% Following oral administration of dosages of 1,000 mg to 2,000 mg to steady state, the mean plasma clearance of 6MNA is 20 to 30 mL/min and the elimination half-life is approximately 24 hours.
      40. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:264df44a-e294-4d9b-9113-92859cb08c20 (opens source in a new tab)

        Nabumetone label

        Version not recorded · Effective date not recorded

        ites 34% Total % Dose: 73% Following oral administration of dosages of 1,000 mg to 2,000 mg to steady state, the mean plasma clearance of 6MNA is 20 to 30 mL/min and the elimination half-life is approximately 24 hours.
      41. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:419c597f-6a6f-4420-b240-7dc4c223387e (opens source in a new tab)

        Nabumetone label

        Version not recorded · Effective date not recorded

        ites 34% Total % Dose: 73% Following oral administration of dosages of 1,000 mg to 2,000 mg to steady state, the mean plasma clearance of 6MNA is 20 to 30 mL/min and the elimination half-life is approximately 24 hours.
      42. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:16e76e29-9315-40c0-b1d6-8d91961063cf (opens source in a new tab)

        Nabumetone label

        Version not recorded · Effective date not recorded

        ites 34% Total % Dose: 73% Following oral administration of dosages of 1,000 mg to 2,000 mg to steady state, the mean plasma clearance of 6MNA is 20 to 30 mL/min and the elimination half-life is approximately 24 hours.
      43. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3745775e-e11a-01db-e063-6294a90a9b52 (opens source in a new tab)

        Nabumetone label

        Version not recorded · Effective date not recorded

        ites 34% Total % Dose: 73% Following oral administration of dosages of 1,000 mg to 2,000 mg to steady state, the mean plasma clearance of 6MNA is 20 to 30 mL/min and the elimination half-life is approximately 24 hours.
      44. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d9ca2484-7293-7db6-e053-2995a90a0f13 (opens source in a new tab)

        Nabumetone label

        Version not recorded · Effective date not recorded

        ites 34% Total % Dose: 73% Following oral administration of dosages of 1,000 mg to 2,000 mg to steady state, the mean plasma clearance of 6MNA is 20 to 30 mL/min and the elimination half-life is approximately 24 hours.
      45. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:583602ff-dbbe-4369-afa9-b917734ac9b1 (opens source in a new tab)

        Nabumetone label

        Version not recorded · Effective date not recorded

        ites 34% Total % Dose: 73% Following oral administration of dosages of 1,000 mg to 2,000 mg to steady state, the mean plasma clearance of 6MNA is 20 to 30 mL/min and the elimination half-life is approximately 24 hours.
      46. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:079a8a9e-6d71-414a-83f3-ef68e323c1fd (opens source in a new tab)

        Nabumetone label

        Version not recorded · Effective date not recorded

        ites 34% Total % Dose: 73% Following oral administration of dosages of 1,000 mg to 2,000 mg to steady state, the mean plasma clearance of 6MNA is 20 to 30 mL/min and the elimination half-life is approximately 24 hours.
      47. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0870c3c9-bfce-4722-8779-8775644196d3 (opens source in a new tab)

        Nabumetone label

        Version not recorded · Effective date not recorded

        ites 34% Total % Dose: 73% Following oral administration of dosages of 1,000 mg to 2,000 mg to steady state, the mean plasma clearance of 6MNA is 20 to 30 mL/min and the elimination half-life is approximately 24 hours.
      48. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:26037234-daca-4f1a-a7a7-0871f77283f0 (opens source in a new tab)

        Nabumetone label

        Version not recorded · Effective date not recorded

        ites 34% Total % Dose: 73% Following oral administration of dosages of 1,000 mg to 2,000 mg to steady state, the mean plasma clearance of 6MNA is 20 to 30 mL/min and the elimination half-life is approximately 24 hours.
      49. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:065fdacc-739e-4b46-bebc-044b5c11bbbb (opens source in a new tab)

        Nabumetone label

        Version not recorded · Effective date not recorded

        ites 34% Total % Dose: 73% Following oral administration of dosages of 1,000 mg to 2,000 mg to steady state, the mean plasma clearance of 6MNA is 20 to 30 mL/min and the elimination half-life is approximately 24 hours.
      50. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0be7ee60-2706-43ed-98ec-b89cd4e2b57c (opens source in a new tab)

        Nabumetone label

        Version not recorded · Effective date not recorded

        ites 34% Total % Dose: 73% Following oral administration of dosages of 1,000 mg to 2,000 mg to steady state, the mean plasma clearance of 6MNA is 20 to 30 mL/min and the elimination half-life is approximately 24 hours.

  10. Projected row 1050

    Medicine slug
    nadolol
    Compared field
    halfLife
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    23
    Source count
    23
    Agreement rate
    1
    Recorded readings

    1. 20 to 24 hours

      Numeric value
      20
      Unit
      hours
      Source records
      23

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 23 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4580b85b-437c-4c52-bf31-5976968ecd5c (opens source in a new tab)

        Nadolol label

        Version not recorded · Effective date not recorded

        The half-life of therapeutic doses of nadolol is about 20 to 24 hours, permitting once-daily dosage.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9e8e129d-cb17-45fc-b3e2-2600c0166463 (opens source in a new tab)

        Nadolol label

        Version not recorded · Effective date not recorded

        The half-life of therapeutic doses of nadolol is about 20 to 24 hours, permitting once-daily dosage.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a0a38f9b-268d-4463-881d-5bee6cd92e8a (opens source in a new tab)

        Nadolol label

        Version not recorded · Effective date not recorded

        The half-life of therapeutic doses of nadolol is about 20 to 24 hours, permitting once-daily dosage.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2fc1f850-9653-4082-929a-926b644810e7 (opens source in a new tab)

        Nadolol label

        Version not recorded · Effective date not recorded

        The half-life of therapeutic doses of nadolol is about 20 to 24 hours, permitting once-daily dosage.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0bd202e3-c673-4945-b828-1a5bc6a896ae (opens source in a new tab)

        Nadolol label

        Version not recorded · Effective date not recorded

        The half-life of therapeutic doses of nadolol is about 20 to 24 hours, permitting once-daily dosage.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:64a788d0-b7f0-4f39-8adb-ab68870ecfa5 (opens source in a new tab)

        Nadolol label

        Version not recorded · Effective date not recorded

        The half-life of therapeutic doses of nadolol is about 20 to 24 hours, permitting once-daily dosage.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e2e24b14-0169-4028-828a-894ad3c2ba55 (opens source in a new tab)

        Nadolol label

        Version not recorded · Effective date not recorded

        The half-life of therapeutic doses of nadolol is about 20 to 24 hours, permitting once-daily dosage.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:85b4b931-51c4-4326-88ea-708dde8323d4 (opens source in a new tab)

        Nadolol label

        Version not recorded · Effective date not recorded

        The half-life of therapeutic doses of nadolol is about 20 to 24 hours, permitting once daily dosage.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5c6737f8-8fd8-4d8f-a66a-e99d3b64e1dd (opens source in a new tab)

        Nadolol label

        Version not recorded · Effective date not recorded

        The half-life of therapeutic doses of nadolol is about 20 to 24 hours, permitting once-daily dosage.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f11553f1-18ec-41b0-a7ad-1c9f21ef2c9f (opens source in a new tab)

        Nadolol label

        Version not recorded · Effective date not recorded

        The half-life of therapeutic doses of nadolol is about 20 to 24 hours, permitting once-daily dosage.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9acc0c81-4145-43cc-b31a-7b1e3313259d (opens source in a new tab)

        Nadolol label

        Version not recorded · Effective date not recorded

        The half-life of therapeutic doses of nadolol is about 20 to 24 hours, permitting once-daily dosage.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c899eedb-4113-45da-acc3-8e181250a7d8 (opens source in a new tab)

        Nadolol label

        Version not recorded · Effective date not recorded

        The half-life of therapeutic doses of nadolol is about 20 to 24 hours, permitting once-daily dosage.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5a8014fb-9b65-4457-bfd5-0ab7e6de330e (opens source in a new tab)

        Nadolol label

        Version not recorded · Effective date not recorded

        The half-life of therapeutic doses of nadolol is about 20 to 24 hours, permitting once-daily dosage.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6ab029aa-dfe0-4abb-8c7f-2692fe6a2368 (opens source in a new tab)

        Nadolol label

        Version not recorded · Effective date not recorded

        The half-life of therapeutic doses of nadolol is about 20 to 24 hours, permitting once-daily dosage.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:15822faf-6924-4a63-a4e1-6058b308708c (opens source in a new tab)

        Nadolol label

        Version not recorded · Effective date not recorded

        The half-life of therapeutic doses of nadolol is about 20 to 24 hours, permitting once-daily dosage.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:33dcfdb9-1741-71e1-e063-6294a90afdff (opens source in a new tab)

        Nadolol label

        Version not recorded · Effective date not recorded

        The half-life of therapeutic doses of nadolol is about 20 to 24 hours, permitting once-daily dosage.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c154d99c-e4fb-41d0-8fac-e1982672e8d7 (opens source in a new tab)

        Nadolol label

        Version not recorded · Effective date not recorded

        The half-life of therapeutic doses of nadolol is about 20 to 24 hours, permitting once-daily dosage.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0d66548a-231e-4104-be0c-c6ce1586b46c (opens source in a new tab)

        Nadolol label

        Version not recorded · Effective date not recorded

        The half-life of therapeutic doses of nadolol is about 20 to 24 hours, permitting once-daily dosage.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:44c5352d-89f8-4bd3-9479-1069304562ca (opens source in a new tab)

        Nadolol label

        Version not recorded · Effective date not recorded

        The half-life of therapeutic doses of nadolol is about 20 to 24 hours, permitting once-daily dosage.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0a2acdc0-aab6-462e-a377-67a0f3d55ec6 (opens source in a new tab)

        Nadolol label

        Version not recorded · Effective date not recorded

        The half-life of therapeutic doses of nadolol is about 20 to 24 hours, permitting once-daily dosage.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9cf4ca73-2d38-44c2-a522-d44d536b5e55 (opens source in a new tab)

        Nadolol label

        Version not recorded · Effective date not recorded

        The half-life of therapeutic doses of nadolol is about 20 to 24 hours, permitting once-daily dosage.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2d126308-c58d-4950-9dcb-eaadb1a2054f (opens source in a new tab)

        Nadolol label

        Version not recorded · Effective date not recorded

        The half-life of therapeutic doses of nadolol is about 20 to 24 hours, permitting once-daily dosage.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8a224f90-24a5-411e-ac26-6496a1930f3a (opens source in a new tab)

        Nadolol label

        Version not recorded · Effective date not recorded

        The half-life of therapeutic doses of nadolol is about 20 to 24 hours, permitting once-daily dosage.

Access

Query or download the projection

View this filtered page as JSONDownload up to 200 filtered CSV rows
GET /api/datasets/source-consensus?limit=10&offset=1040

Allowed query parameters

q
Case-insensitive text search over the public fields named for this dataset.
state
Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
field
Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
limit / offset
Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.

Reuse and corrections

Keep the boundary attached

CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.

Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.

Read the correction policy